Becton, Dickinson and Company (BDX) Stock Rating Reaffirmed by Piper Jaffray Companies

Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “buy” rating reaffirmed by stock analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday. They currently have a $213.00 target price on the medical instruments supplier’s stock. Piper Jaffray Companies’ target price points to a potential upside of 5.34% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their target price for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation reissued a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a report on Monday, July 17th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Finally, Cowen and Company reissued an “outperform” rating and set a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $196.93.

Becton, Dickinson and (NYSE:BDX) traded down 0.82% during trading on Tuesday, reaching $202.20. 1,129,041 shares of the company traded hands. The company’s 50-day moving average is $199.97 and its 200 day moving average is $190.93. Becton, Dickinson and has a 12 month low of $161.29 and a 12 month high of $206.63. The company has a market cap of $46.01 billion, a PE ratio of 58.56 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter last year, the firm posted $2.35 EPS. The company’s quarterly revenue was down 5.1% on a year-over-year basis. On average, analysts anticipate that Becton, Dickinson and will post $9.46 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Stock Rating Reaffirmed by Piper Jaffray Companies” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2887234/becton-dickinson-and-company-bdx-stock-rating-reaffirmed-by-piper-jaffray-companies.html.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BDX. North Star Investment Management Corp. lifted its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the period. Almanack Investment Partners LLC. acquired a new position in Becton, Dickinson and in the first quarter valued at approximately $105,000. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the period. QCI Asset Management Inc. NY lifted its stake in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 60 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares during the period. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.